Alcyone Lifesciences is a Concord, Massachusetts-based medical device company founded in 2010. It develops a platform technology for delivery of therapy to the brain and a novel technology to manage CSF (cerebrospinal fluid) shunt occlusions. The company's products target difficult neuropathological conditions. It intends to use the funds from the Series B to further develop its brain-delivery platform and the CSF shunt occlusion technology. The founding team includes PJ Anand (CEO), Adam Fleisher, MD, and William Olbricht, PhD. Alcyone Lifesciences is focused on developing products for the treatment of difficult and chronic neuropathological conditions. The company disclosed in a regulatory filing that it raised $1.8 million in its first round of venture capital. Fourteen investors participated in the offering. A principal of MPM Capital is a co-founder of the company. The filing lists AYER, MA as the company's location. The disclosed capital represents the company's first venture financing.

Total raised

$6M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2014